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Criteria to select molecular targets for anti-fibrotic therapy
J. H. W. Distler1 and O. Distler2
Tissue fibrosis is a major cause of morbidity and mortality in SSc. An increasing number of promising molecular targets for anti-fibrotic
therapies have been described recently. However, the number of patients eligible for clinical trials is limited in SSc. The present article
discusses criteria to select the most promising molecular targets for clinical trials in SSc. Based on consensus among experts, important
criteria for the selection of molecular-based therapies were as follows: First, there should be strong experimental evidence that targeting the
molecule of interest inhibits fibrosis. Optimally, the anti-fibrotic effects should be confirmed in at least two complementary animal models of
SSc. Second, inhibitors of the molecule of interest should be clinically available. Third, clinical experience with the drug of interest in other
diseases hastens the initiation of clinical trials and reduces the risk of unexpected side-effects. Finally, funding for clinical trials with the drug
of interest in SSc should be available. We propose that the priority of novel targets for evaluation in clinical trials in SSc might be selected
based on these consensus criteria.
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The pathogenesis of tissue fibrosis is multifactorial, but fibrosis is
mainly caused by an overproduction of extracellular matrix by
activated fibroblasts/myofibroblasts. The resulting accumulation
of extracellular matrix proteins disrupts the physiological tissue
structure and often leads to organ dysfunction. Tissue fibrosis is
a major cause of morbidity and mortality in SSc, but specific anti-
fibrotic therapies are not yet available for clinical use. Thus, the
development of novel anti-fibrotic therapies is a major goal in SSc
research.
Lately, a number of promising molecular targets for the
treatment of fibrosis in SSc have been characterized. This includes
Abelson kinase (Abl) [1, 2], steroid receptor coactivator (Src)
kinases [3], Rho-associated kinases (ROCK) [4], histone deacety-
lases (HDACs) [5], monocyte chemoattractant protein-1 (MCP-1,
CCL2) [6], adenosine A2A receptors [7] and proteasomal
degradation [8]. In addition, TGF-, connective tissue growth
factor (CTGF), PDGFs and ET-1 are well-established key players
in the pathogenesis of SSc. Their mechanisms of action, their role
in fibrosis and their level of evidence as important molecular
factors driving fibrosis are described in other contributions in this
supplement. Interestingly, it is a common feature of many of these
profibrotic molecules that inhibitors are already in clinical use for
other indications (e.g. ET-receptor antagonists, imatinib mesylate
and other c-Abl inhibitors, the Rho-kinase inhibitor fasudil) or
are in clinical development (e.g. TGF- inhibitors, PDGF
inhibitors, HDAC inhibitors and others).
Thus, therapies for many of these promising molecular targets
are already available for clinical trials or will be available in the
near future. According to established guidelines, the potentially
disease-modifying drugs should be tested in patients with early
dcSSc because they are at greater risk for the development of
progressive skin involvement, severe organ damage and death [9].
At best, studies should be designed as randomized, double-blind,
placebo-controlled trials and should have a reasonable observa-
tion period of at least 1 yr. These rather strict requirements
together with the increasing number of available interventions
create a specific problem: SSc is an orphan disease with a limited
number of patients available for clinical trials, in particular when
patients with early dcSSc are targeted. Thus, it will not be feasible
to test all molecular-targeted therapies at the same time, and there
is the necessity to select those from the list of potentially disease-
modifying agents that are most promising and should be tested
first in clinical trials.
However, it is unclear according to which criteria such a
priority list should be established. It was thus the aim of this
exercise to create consensus on such criteria among SSc experts.
Thirty-five scientists from Europe and the United States with
expertise in basic and/or clinical science met at a face to face
meeting in Florence, Italy, in October 2007. Potential criteria were
first discussed in a breakout session. The preliminary consensus
from the breakout session was then presented to the remaining
group. In the case of disagreement it was solved by discussion. The
group finally agreed to the criteria presented below and in Table 1.
It needs to be emphasized that these criteria focus on molecular
targets, while other approaches such as cell-based therapies and
unspecific immunosuppressive therapies, were not addressed.
Efficacy in preclinical models
Demonstration of the efficacy of the drug of interest in preclinical
models of fibrosis was defined as the most important criterion.
The level of evidence of an anti-fibrotic effect in preclinical models
can be categorized into three levels (level C to level A). In general,
it is a prerequisite for all drugs that the pathway of interest is
activated and operative in the human disease. This can be best
proven in biosamples from SSc patients, in which tissue samples
are most meaningful. In addition, the expert group agreed that an
optimal molecular target should play a key role in the
immunological, vascular as well as fibrotic pathogenesis of SSc.
Drugs with Evidence Level C have been demonstrated to be
anti-fibrotic in vitro only. Optimally, the mechanisms of action of
novel compounds should be determined including downstream
molecules and intracellular signalling pathways. However, the
results from these studies are limited by their in vitro nature,
and a positive finding on the in vitro level does not necessarily
mean that it can be confirmed in vivo [10].
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TABLE 1. Criteria to determine the priority of novel compounds for clinical trials
Criteria to determine the priority of novel compounds for clinical trials
(1) Evidence for anti-fibrotic effects in preclinical models
Level C: in vitro data
Level B: SSc animal model
Level A: Several SSc animal models
(2) Availability of the inhibitor for clinical trials
(3) Clinical experience
(4) Availability of funding
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Thus, for Evidence Level B, the anti-fibrotic effects of the drug of
interest should in addition be proven in vivo in an animal model of
SSc. During recent years, a number of animal models have been
established for SSc. This includes among others the mouse models
of bleomycin-induced dermal fibrosis, sclerodermatous chronic
graft vs host disease, tight skin-1 mice and TBR1CA Cre-ER mice,
Fra-2 transgenic mice as well the UCD 200 chicken model. These
animal models cover different aspects and mechanisms of SSc
pathogenesis. For instance, in the mouse model of bleomycin-
induced dermal fibrosis, repeated injections of bleomycin, a
profibrotic chemotherapeutic drug, in defined areas of the upper
back induces a localized dermal fibrosis. The underlying molecular
mechanisms are similar to that observed in SSc with infiltration of
T cells and macrophages in lesional skin and TGF- and PDGF-
dependent activation of resident fibroblasts. In contrast, TBR1CA
Cre-ER mice are less dependent on inflammatory infiltrates. This
model is based on the expression of a constitutively active TGF-
receptor 1, which is selectively induced in fibroblasts upon feeding
of 4-hydroxytamoxifen. The post-natal induction of TGF-
signalling leads to an SSc-like disease with progressive dermal
fibrosis and a vasculopathy with fibrotic thickening of the walls of
smaller vessels. These examples illustrate that while all models are
useful for specific aspects of SSc, none of them fully reflects the
human pathogenesis.
Drugs that fulfil Evidence Level A should therefore be tested in
at least two of the animal models mentioned earlier addressing
different aspects of the disease. At best, the anti-fibrotic effects
should also be shown in different organs involved in SSc, e.g. the
lungs and skin, because the profibrotic mechanisms might differ
substantially between organs.
Availability of drugs
Besides efficacy, another important criterion is that the inhibitor of
interest is either already available or will become available soon for
clinical trials. Therapies that are just entering early clinical
development would delay the onset of clinical trials and thus
have a lower priority for evaluation in clinical trials compared with
drugs that are already available.
Clinical experience
Furthermore, clinical experience with the drug of interest is
desirable and increases the priority of the drug for evaluation in
clinical trials. Previous experience with the drug in other diseases
reduces the risk of unexpected side-effects and enhances the safety
for SSc patients. Also, experiences in other diseases help to avoid
lack of efficacy of the drug on its target and pharmacokinetic
problems.
Funding
Finally, large-scale randomized controlled trials with an acceptable
level of quality are only feasible when funding is available. Most
often, funding for large-scale clinical trials nowadays comes from
pharmaceutical industry. With the definition of orphan diseases
and its related financial advantages, the interest of pharmaceutical
companies in rare diseases such as SSc will increase in the near
future. In addition, national and international funding agencies
support clinical studies that are independent from industry.
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Rheumatology key messages
 An increasing number of promising molecular targets for the
treatment of fibrosis in SSc have been characterized.
 Inhibitors of these key molecules are clinically available and await
testing in clinical trials in SSc.
 However, the number of patients eligible for clinical trials in SSc
(e.g. patients with early diffuse disease) is limited.
 Therefore, experts developed criteria to develop a priority list of
the most promising molecular targets for anti-fibrotic therapies that
should be first tested in clinical trials.
 The criteria included: (i) evidence level for anti-fibrotic effects in
preclinical models; (ii) availability of drugs; (iii) clinical experience
in other indications; and (iv) availability of funding.
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